---
company: NEKTAR THERAPEUTICS
ticker: NKTR
form: 8-K
filed: 2026-05-07
accession: 0001213900-26-053369
source: https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/
---

# Nektar Therapeutics (NKTR) earnings release, May 7, 2026

Nektar Therapeutics (NKTR) · Form 8-K, Item 2.02 · Filed 2026-05-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/)

Exhibit

99.1

Nektar

Therapeutics Reports First Quarter 2026 Financial Results

SAN

FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.

Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar’s cash and marketable securities at March 31, 2026, exclude net proceeds of approximately $351 million from the secondary offering completed by the Company on April 23, 2026.

“2026 is shaping up to be a defining year for Nektar and for our lead biologic candidate rezpegaldesleukin,” said Howard W. Robin,

President and Chief Executive Officer of Nektar. “We have now shown that longer-term treatment with rezpegaldesleukin continues to deepen clinical responses in two distinct immune-mediated diseases, reinforcing our belief that this novel Treg mechanism can transform the treatment paradigm for autoimmune disease. The Phase 3 ZENITH-AD program in atopic dermatitis will initiate by July, and we will have our End-of-Phase 2 meeting for alopecia areata this quarter. With a substantially strengthened balance sheet and over one billion dollars in cash and investments, we are well positioned to advance rezpegaldesleukin into late-stage development with strong scientific and clinical conviction.”

Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.

Total operating costs and expenses in the first quarter of 2026 were $49.9 million as compared to $55.0 million in the first quarter of 2025. Operating expenses decreased due to a decrease in G&A expenses, partially offset by an increase in R&D expenses.

R&D expense in the first quarter of 2026 was $35.7 million as compared to $30.5 million for the first quarter of 2025.

R&D expense increased primarily due to increased expenses for the development of rezpegaldesleukin as we commenced activities to support a Phase 3 program in atopic dermatitis.

G&A expense was $13.4 million in the first quarter of 2026 as compared to $24.3 million in the first quarter of 2025.

G&A expense decreased primarily due to a decrease in legal expenses.

Our non-cash loss from our equity method investment in Gannet BioChem was $1.8 million in the first quarter of 2026, as compared to

$4.5 million in the first quarter of 2025.

Net loss for the first quarter of 2026 was $44.9 million or $1.82 basic and diluted net loss per share as compared to net loss of $50.9 million or $3.62¹ basic and diluted loss per share in the first quarter of 2025.

Recent

Business Highlights

Upcoming

Milestones

Conference

Call to Discuss First Quarter 2026 Financial Results

Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time on May 7, 2026.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 7, 2026.

To access the conference call, please pre-register at Nektar

Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar

Therapeutics

Nektar

Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase

2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.²

Cautionary

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements which can be identified by words such as: “can,” “develop,”

“potential,” “expand,” “address,” “may,” “plan,” “upcoming” and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the safety and efficacy profile and therapeutic potential of, and future development plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, and potential patient preferences and market adoption related thereto, and plans and timing of future clinical trials and data releases.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements... (truncated), NKTR-0166 and NKTR-422 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are in clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) data reported from ongoing clinical trials are necessarily interim data only and the final results will change based on continuing observations; (v) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (vi) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in the United States; (vii) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and

(viii) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange

Commission on March 13, 2026. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

For

Investors:

Vivian

Wu

628-895-0661

VWu@nektar.com

Corey

Davis, Ph.D.

LifeSci

Advisors

212-915-2577 cdavis@lifesciadvisors.com

For

Media:

Susan

Roberts

LifeSci

Communications

202-779-0929 sroberts@lifescicomms.com³

NEKTAR

THERAPEUTICS

## Financial statements

### Income Statement (Three months ended March 31, — (Unaudited) (in thousands))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025(2) |
|---|---:|---:|
| Revenue: | Non-cash royalty revenue related to the sales of future royalties | 10,861 | 10,460 |
| Revenue: | Total revenue | 10,861 | 10,460 |
| Operating costs and expenses: | Research and development | 35,680 | 30,480 |
| Operating costs and expenses: | General and administrative | 13,439 | 24,346 |
| Operating costs and expenses: | Restructuring and impairment | 796 | 169 |
| Operating costs and expenses: | Total operating costs and expenses | 49,915 | 54,995 |
| Operating costs and expenses: | Loss from operations | -39,054 | -44,535 |
| Non-operating income (expense): | Non-cash interest expense on liabilities related to the sales of future royalties | -7,942 | -4,974 |
| Non-operating income (expense): | Interest income | 4,242 | 2,874 |
| Non-operating income (expense): | Other income (expense), net | -336 | 266 |
| Non-operating income (expense): | Total non-operating income (expense), net | -4,036 | -1,834 |
| Non-operating income (expense): | Loss before provision for income taxes and equity method investment | -43,090 | -46,369 |
| Non-operating income (expense): | Provision for income taxes | 64 | 52 |
| Non-operating income (expense): | Loss before equity method investment | -43,154 | -46,421 |
| Non-operating income (expense): | Loss from equity method investment | -1,750 | -4,461 |
| Non-operating income (expense): | Net loss | -44,904 | -50,882 |
| Non-operating income (expense): | Basic and diluted net loss per share | -1.82 | -3.62 |
| Non-operating income (expense): | Weighted average shares outstanding used in computing basic and diluted net loss per share | 24,736,066 | 14,063,402 |

### Balance Sheet (March 31, 2026 — (Unaudited) (in thousands))

| | March 31, 2026 | December 31, 2025(1) |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 149,578 | 15,116 |
| Current assets: | Short-term investments | 419,026 | 230,636 |
| Current assets: | Other current assets | 20,437 | 20,514 |
| Current assets: | Total current assets | 589,041 | 266,266 |
| Current assets: | Long-term investments | 162,993 |  |
| Current assets: | Other assets | 11,237 | 14,140 |
| Current assets: | Total assets | 763,271 | 280,406 |
| Current liabilities: | Accounts payable | 10,026 | 10,770 |
| Current liabilities: | Accrued expenses | 25,151 | 22,271 |
| Current liabilities: | Operating lease liabilities, current portion | 22,531 | 20,495 |
| Current liabilities: | Total current liabilities | 57,708 | 53,536 |
| Current liabilities: | Operating lease liabilities, less current portion | 60,631 | 65,256 |
| Current liabilities: | Liabilities related to the sales of future royalties, net | 60,270 | 63,157 |
| Current liabilities: | Other long-term liabilities | 8,446 | 8,625 |
| Current liabilities: | Total liabilities | 187,055 | 190,574 |
| Stockholders’ equity: | Common stock | 3 | 2 |
| Stockholders’ equity: | Capital in excess of par value | 4,382,437 | 3,850,099 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | -1,034 | 17 |
| Stockholders’ equity: | Accumulated deficit | -3,805,190 | -3,760,286 |
| Stockholders’ equity: | Total stockholders’ equity | 576,216 | 89,832 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 763,271 | 280,406 |
